Torapsel Biosimilar – Anti-LECAM3 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2037; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Torapsel Biosimilar is a fusion protein that has been developed as a potential therapeutic agent for the treatment of LECAM3-associated diseases. This protein is a biosimilar of the humanized anti-LECAM3 antibody, which has shown promising results in preclinical studies. In this article, we will provide a detailed description of the structure, activity, and potential applications of Torapsel Biosimilar.
Torapsel Biosimilar is a fusion protein that consists of two components – the anti-LECAM3 antibody and the Torapsel protein. The anti-LECAM3 antibody is a humanized monoclonal antibody that specifically binds to LECAM3, a cell adhesion molecule that is overexpressed in various diseases, including cancer and autoimmune disorders. The Torapsel protein is a fusion partner that helps to stabilize the antibody and enhance its activity.
The anti-LECAM3 antibody portion of Torapsel Biosimilar is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains contain the variable region, which is responsible for binding to LECAM3, and the constant region, which is responsible for effector functions. The light chains also contain a variable region and a constant region. The Torapsel protein is a small protein that is derived from a bacterial protein and acts as a linker between the heavy and light chains of the antibody.
The primary activity of Torapsel Biosimilar is its ability to bind to LECAM3 with high specificity and affinity. This binding inhibits the function of LECAM3, which is involved in cell adhesion and migration. By blocking LECAM3, Torapsel Biosimilar can inhibit the growth and spread of cancer cells and reduce inflammation in autoimmune disorders.
In addition to its binding activity, Torapsel Biosimilar also has effector functions that are mediated by the constant region of the antibody. These effector functions include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ADCC involves the recruitment of immune cells, such as natural killer cells, to kill target cells that are bound by the antibody. CDC, on the other hand, involves the activation of the complement system, which leads to the lysis of target cells.
Torapsel Biosimilar has shown promising results in preclinical studies and has the potential to be used in various therapeutic applications. Its primary application is in the treatment of LECAM3-associated diseases, such as cancer and autoimmune disorders. By targeting LECAM3, Torapsel Biosimilar can inhibit the growth and spread of cancer cells and reduce inflammation in autoimmune disorders.
In addition to its potential in the treatment of LECAM3-associated diseases, Torapsel Biosimilar can also be used as a research tool. Its high specificity and affinity for LECAM3 make it a valuable tool for studying the role of LECAM3 in different diseases. Furthermore, its effector functions can be utilized to study the mechanisms of ADCC and CDC in cancer and autoimmune disorders.
In summary, Torapsel Biosimilar is a fusion protein that combines the specificity and affinity of the anti-LECAM3 antibody with the stability and activity-enhancing properties of the Torapsel protein. This fusion protein has the potential to be used as a therapeutic agent for the treatment of LECAM3-associated diseases, as well as a research tool for studying LECAM3 and its role in various diseases. With further development and clinical trials, Torapsel Biosimilar could become a valuable addition to the arsenal of treatments for cancer and autoimmune disorders.
ProteoGenix catalogue number PX-TA2037. For research use only.
Target: Torapsel Biosimilar – Anti-LECAM3 fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Torapsel Biosimilar – Anti-LECAM3 fusion protein – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
